

## **Oncology Test Request**

<b>Client Information</b> (requ	uired)		<b>Patient Informa</b>	ntion (required)		
Client Name	· ·		Patient ID (Medical F	Record No.)		
Client Account No.			Patient Name (Last, Fi	irst, Middle)		
Client Phone	Client Or	der No.	Sex	Female	Birth D	Date (mm-dd-yyyy)
Address	l		Collection Date (mm-	dd-yyyy)	Time	□ am □ pm
City	State	Zip Code	Specimens Pro	vided (required)		
Submitting Provider In		uired)	☐ Blood☐ Bone marrow	☐ Paraffin blo No. sent: _		☐ Tissue No. sent:
Submitting/Referring Provider	Name (Last, First)		☐ Fixed cells ☐ Cultured cells	Indicate sou	ırce:	☐ Frozen ☐ Fixed formalin
Fill in only if Call Back is req			□ DNA			☐ Wet tissue
Phone (with area code)	Fax (with are	a code)	☐ Lymph node			☐ Other fixative
Provider's National I.D. (NPI)			□ Spleen	☐ Slides No. sent: _		Type:
*Fax number given must be from a fax HIPAA regulation.	machine that complies	with applicable				Anatomic site:
<b>Pathologist Informatio</b>	n (required)		CBC Results			-
Submitting/Referring Provider	Name (Last, First)		HB:	RBC:		WBC:
			HCT:		!	PLT:
Phone (with area code)	Fax (with are	a code)		fixed in 10% neutr		red formalin within
Provider's National I.D. (NPI)				cal collection time?		☐ Yes ☐ No
*Fax number given must be from a fax HIPAA regulation.	x machine that complies	with applicable	6 to 72 hours?	Jeen fixed iii 10%		ouffered formalin for      Yes    No
<b>New York State Patients: Informed</b>	Consent for Genetic T	esting	Pathology/Clini	cal Diagnosis	(require	ed)
"I hereby confirm that informe individual legally authorized to or the individual's provider's of	do so and is on file	0 ,	Include a brief history, perfor referral.	rtinent laboratory resul	ts, suspec	ted diagnosis, and reason
Signature						
Note: It is the client's responsibility to	maintain documetation	of the order.				
MCL Internal Use Only			ICD-10 Diagnosis Co	ode		
Ship specimens to: Mayo Clinic Laboratories 3050 Superior Drive NW			Billing Information  • An itemized invoi  • Payment terms an	ce will be sent each more net 30 days.	onth.	

T729

Rochester, MN 55901

**Customer Service: 855-516-8404** 

Call the Business Office with billing related questions:

800-447-6424 (US and Canada) 507-266-5490 (outside the US)

#### **Patient Information (required)**

Patient ID (Medical Record No.)	Client Account No.
Patient Name (Last, First, Middle)	Client Order No.
Birth Date (mm-dd-yyyy)	

#### **FEATURED ONCOLOGY TESTING**

PD-L1 Imm	nunohistochemical stains
□ SP263	Programmed Death-Ligand 1 (PD-L1) (SP263), Semi-Quantitative Immunohistochemistry, Manual
□ SP142	Programmed Death-Ligand 1 (PD-L1) (SP142), Semi-Quantitative Immunohistochemistry, Manual
□ 22C3	Programmed Death-Ligand 1 (PD-L1) (22C3), Semi-Quantitative Immunohistochemistry, Manual
Microsatel	lite Instability (MSI)/Mismatch Repair
Microsatel  TMSI	lite Instability (MSI)/Mismatch Repair Microsatellite Instability, Tumor
	- , ,
☐ TMSI	Microsatellite Instability, Tumor Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor
☐ TMSI☐ IHC	Microsatellite Instability, Tumor Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor
☐ TMSI☐ IHC	Microsatellite Instability, Tumor  Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor on Testing

Next-Gene	ration Sequencing (NGS) Panels
□ GISTP	Gastrointestinal Stromal Tumor (GIST) Targeted Gene Panel, Next-Generation Sequencing, Tumor
□ LNGPR	Lung Cancer-Targeted Gene Panel with Rearrangement, Tumor
☐ MCSTP	MayoComplete Solid Tumor Panel, Next-Generation Sequencing, Tumor
☐ MELP	Melanoma Targeted Gene Panel, Next- Generation Sequencing, Tumor
□ NONCP	Neuro-Oncology Expanded Gene Panel with Rearrangement, Tumor
□ RASFP	RAS/RAF Targeted Gene Panel, Next-Generation Sequencing, Tumor
□ SARCP	Sarcoma Targeted Gene Fusion/ Rearrangement Panel, Next-Generation Sequencing, Tumor
□ CAPN	Solid Tumor-Targeted Cancer Gene Panel, Next-Generation Sequencing

Myxoid/Round Cell Liposarcoma, 12q13

(DDIT3 or CHOP) Rearrangement, FISH,

☐ DDITF

☐ ERPR

☐ KI67B

☐ HERBA

Chromosoi	mal Microarray
☐ CMAPT	Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded
Cell-Free D	DNA (cfDNA) Testing
□ BRAFB	Cell-Free DNA BRAF V600 Test, Blood
□ EGFRD	EGFR Exon 18, 19, 20, 21, Mutation Analysis, Cell-Free DNA, Plasma
□ T790M	Cell-Free DNA EGFR T790M Mutation Analysis, Blood
☐ KRASD	Cell-Free DNA KRAS 12, 13, 61, 146, Blood

# PATHOLOGY PATHC Pathology Consultation Appropriate stains and ancillary testing may be performed in order to render an accurate diagnosis

#### PATHOLOGY: TARGETED TUMOR TESTING

#### **Bone and Soft Tissue**

☐ FOXOF Alveolar Rhabdomyosarcoma (ARMS), 13q14 (FOXO1 or FKHR) Rearrangement, FISH, Tissue ☐ ETV6F ETV6 (12p13.2) Rearrangement, FISH,

Tissue

☐ TFE3F Alveolar Soft Part Sarcoma (ASPS)/Renal

Cell Carcinoma (RCC), Xp11.23 (TFE3), FISH, Tissue

☐ MASF Angiosarcoma, MYC (8q24) Amplification, FISH, Tissue

☐ CTNNB Beta-Catenin (CTNNB1) Mutation

Analysis, Tumor

☐ ESTUF Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1), 17p13.3 (YWHAE) Rearrangement, FISH, Tissue

☐ EWSF Ewing Sarcoma (EWS), 22q12 (EWSR1) Rearrangement, FISH, Tissue

☐ IMTF Inflammatory Myofibroblastic Tumors (IMT), 2p23 (ALK) Rearrangement, FISH,

Tissue

☐ MDM2F MDM2 (12q15) Amplification,

Well-Differentiated Liposarcoma/ Atypical Lipomatous Tumor, FISH, Tissue

	Tissue
□ PDGF	PDGFB (22q13), Dermatofibrosarcoma Protuberans/Giant Cell Fibroblastoma, FISH, Tissue
□ SS18F	Synovial Sarcoma (SS), 18q11.2 (SS18 or SYT) Rearrangement, FISH, Tissue
□ USPF	USP6 (17p13), Aneurysmal Bone Cyst and Nodular Fasciitis, FISH, Tissue
Breast	
□ MASF	Angiosarcoma, MYC (8q24) Amplification FISH, Tissue
□ FGF1F	FGFR1 (8p11.2) Amplification, FISH, Tissue
□ H2BR	HER2 Amplification Associated with Breast Cancer, FISH, Tissue
□ ESR1	Estrogen Receptor 1 (ESR1) Mutation Analysis, Tumor
□ ETV6F	ETV6 (12p13.2) Rearrangement, FISH, Tissue
	tochemical assays interpreted image analysis

☐ HERBN	HER2, Breast, Quantitative Immunohistochemistry, Automated with HER2 FISH Reflex
□ HERDM	HER2, Breast, Quantitative Immunohistochemistry, Automated with HER2 FISH Reflex
□ HERDN	HER2, Breast, Quantitative Immunohistochemistry, Automated with HER2 FISH Reflex
Gastrointes	stinal
□ BILA0	Biliary Tract Malignancy, FISH
□ BRAFT	BRAF Mutation Analysis (V600E), Tumor
□ EGFRT	EGFR Gene, Mutation Analysis, 29 Mutation Panel, Tumor
□ PRKAF	Fibrolamellar Carcinoma, 19p13.1 (PRKACA) Rearrangement, FISH, Tissue
☐ FGFR2	FGFR2 (10q26.1) Rearrangement, FISH, Tissue
□ GISTP	Gastrointestinal Stromal Tumor (GIST) Targeted Gene Panel, Next-Generation Sequencing, Tumor
□ H2GE	HER2 Amplification Associated with Gastroesophageal Cancer, FISH, Tissue
□ H2MT	HER2 Amplification, Miscellaneous Tumor, FISH, Tissue
□ HERGM	HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual
□ HERGN	HER2, Gastric/Esophageal, Semi-Quantitative Immunohistochemistry, Manual, No Reflex

Estrogen/Progesterone Receptor,

Ki-67(MIB-1), Breast, Quantitative

Immunohistochemistry, Automated

Immunohistochemistry, Automated

HER2, Breast, Quantitative

with HER2 FISH Reflex

Semi-Quantitative Immunohistochemistry,

## **Patient Information** (required)

Patient ID	(Medical Record No.)			Client Account No.		
Patient Na	me (Last, First, Middle)			Client Order No.		
Birth Date	(mm-dd-yyyy)					
☐ KINET	Ki-67(MIB-1), Gastrointestinal/Pancreatic Neuroendocrine Tumors, Quantitative Immunohistochemistry, Automated	Head and N □ FGF1F		.2) Amplification, FISH,	□ RETF	Lung Cancer, RET (10q11) Rearrangement, FISH, Tissue Lung Cancer, ROS1 (6q22)
☐ METF	MET (7q31), FISH, Tissue	☐ HPVHL		Iomavirus (HPV) High/Low		Rearrangement, FISH, Tissue
☐ ML1HM	MLH1 Hypermethylation Analysis, Tumor			Situ Hybridization	☐ MESOF	Mesothelioma, CDKN2A Fish, Tissue
□ BRMLH	MLH1 Hypermethylation and BRAF Mutation Analysis, Tumor	☐ HPVHR	Human Papil DNA In Situ I	lomavirus (HPV), High-Risk, Hybridization	☐ METF	MET (7q31), FISH, Tissue
☐ IHC	Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor	☐ HPVLR	Human Papil DNA In Situ I	lomavirus (HPV), Low-Risk, Hybridization	ONCOLOGY TESTING	Y: MOLECULAR DIAGNOSTIC
☐ TMSI	Microsatellite Instability, Tumor	□ MAMLF		21) Rearrangement,	Gastrointe	stinal
☐ RASFP	RAS/RAF Targeted Gene Panel,		Mucoepidern FISH, Tissue	noid Carcinoma (MEC),	☐ APCZ	APC Gene, Full Gene Analysis
	Next-Generation Sequencing, Tumor	□ SGTF		Rearrangement, FISH, Tissue	☐ LYNCH	Lynch Syndrome Panel
Genitourina		Melanoma	WITD (0420)	nearrangement, Flori, Floode	☐ MLH1Z	MLH1 Gene, Full Gene Analysis
☐ TFE3F	Alveolar Soft Part Sarcoma (ASPS)/ Renal Cell Carcinoma (RCC),	□ BRAFB	Cell-Free DN	A BRAF V600, Blood	☐ MSH2Z	MSH2 Gene, Full Gene Analysis
	Xp11.23 (TFE3), FISH, Tissue	□ BRAFC		on Analysis (V600),	☐ MSH6Z	MSH6 Gene, Full Gene Analysis
□ GCTF	Germ Cell Tumor (GCT),	Dhai C	Melanoma	on Analysis (voco),	☐ MYHZ	MUTYH Analysis, Full Gene Analysis
	Isochromosome 12p, FISH, Tissue	□ MELP	Melanoma Ta	argeted Gene Panel,	☐ PMS2Z	PMS2 Gene, Full Gene Analysis
☐ H2UR	HER2 Amplification Associated with Urothelial Carcinoma, FISH, Tissue	□ UMM3F		ation Sequencing, Tumor oma, Chromosome 3	□ U1A1V	UDP-Glucuronosyl Transferase 1A1 TA Repeat Genotype, UGT1A1
□ FUROC	UroVysion for Detection of Bladder Cancer, Urine	Naura One	Monosomy, F	FISH, Tissue	□ UGTFG	UDP-Glucuronosyl Transferase 1A1 (UGT1A1), Full Gene Sequencing
□ NUT1F	NUTM1 (15q14) Rearrangement, FISH,	Neuro-Onc			Inherited E	, ,
	Tissue	☐ GLIOF		ion in Gliomas, FISH, Tissue	□ RETZ	RET Proto-Oncogene, Full Gene Analysis
□ PR0F	Prostate Tumor, FISH, Tissue	□ BRAFT		on Analysis (V600E), Tumor	□ SDHP	SDHB, SDHC, SDHD Gene Panel
☐ TFEBF	Renal Cell Carcinoma, 6p21.1 (TFEB) Rearrangement, FISH, Tissue	☐ CMAPT	Formalin-Fix	al Microarray, Tumor, ed Paraffin-Embedded	□ VHLZ	VHL Gene, Full Gene Analysis
Gynecology	у	☐ GCTF	Germ Cell Tu 12p, FISH, Ti	mor (GCT), Isochromosome	PRIMARY	BODY FLUID TESTS
Endometria	I/Uterine Carcinoma	☐ IDH12		rate Dehydrogenase 1 and 2		R DISEASE MONITORING
□ ESTUF	Endometrial Stromal Tumors (EST), 7p15 (JAZF1), 6p21.32 (PHF1),		(IDH1/IDH2)	Mutation Analysis, Tumor oter Methylation, Tumor	OR AIDING	IN THE DIAGNOSIS
	17p13.3 (YWHAE) Rearrangement,	☐ MGMT ☐ NONCP		ogy Expanded Panel with	□ IFG23	Intact Fibroblast Growth Factor 23, Serum
☐ ML1HM	FISH, Tissue MLH1 Hypermethylation Analysis, Tumor		Rearrangeme	ent, Tumor	Breast	
Ovarian Car	cinoma	☐ TERT		ter Analysis, Tumor	□ C2729	Breast Carcinoma-Associated Antigen, Serum
□ XL2	FOXL2 Mutation Analysis, Tumor	Pulmonary		A	☐ CA153	Cancer Antigen 15-3 (CA 15-3), Serum
Lower Anal-	-Genital Tract Carcinoma	□ BRAFT		on Analysis (V600E), Tumor	Endocrine	odnost Antigon 10 0 (OA 10 0), octum
☐ HPVE6	Human Papillomavirus (HPV) High-Risk E6/E7, RNA In Situ Hybridization	□ EGFRT	29 Mutation	Mutation Analysis, Panel, Tumor	Thyroid Car	ncer
☐ HPVHL	Human Papillomavirus (HPV) High/Low Risk, DNA In Situ Hybridization	☐ FGF1F	FGFR1 (8p11 Tissue	.2) Amplification, FISH,	□ CATLN	Calcitonin, Fine-Needle Aspiration Biopsy (FNAB)-Needle Wash, Lymph Node
☐ HPVHR	Human Papillomavirus (HPV), High-Risk,	☐ KRASP	KRAS Somat	ic Mutation Analysis, Tumor	☐ CATN	Calcitonin, Serum
☐ HPVLR	DNA In Situ Hybridization Human Papillomavirus (HPV), Low-Risk,	□ LCAF	Lung Cancer FISH, Tissue	, ALK (2p23) Rearrangement,	□ CEA	Carcinoembryonic Antigen (CEA), Serum Thyraglebulin Mass Spectrometry, Serum
L HEVEN	DNA In Situ Hybridization	□ EGFRR	Lung Cancer Tumor	, EGFR with ALK Reflex,	☐ TGMS ☐ TFNAB	Thyroglobulin Mass Spectrometry, Serum Thyroglobulin, Tumor Marker, Fine-Needle Aspiration Biopsy Needle Wash
		□ LNGPR		-Targeted Gene Panel gement, Tumor	□ HTGR	Thyroglobulin, Tumor Marker Reflex, Serum
		□ LUNGP	Lung Cancer	-Targeted Gene Panel, Tumor	П штер	Thyroglobulin, Tumor Marker, Serum
		□ LUNGR	Lung Cancer Tumor	Rearrangement Testing,	☐ HTG2	Thyrogrobullit, Tuttion Market, Setuill

## **Patient Information** (required)

Patient ID (Medical Record No.)	Client Account No.
Patient Name (Last, First, Middle)	Client Order No.
Birth Date (mm-dd-yyyy)	

No		arina Tumara
		Chromograpia A. Corum
	CGAK	Chromogranin A, Serum
	GAST	Gastrin, Serum
	GLP	Glucagon, Plasma
	NSE	Neuron-Specific Enolase (NSE), Serum
	HPP	Pancreatic Polypeptide, Plasma
	VIP _	Vasoactive Intestinal Polypeptide, Plasma
	uitary Tu	
	ACTH	Adrenocorticotropic Hormone, Plasma
	APGH	Alpha-Subunit Pituitary Tumor Marker, Serum
	FSH	Follicle-Stimulating Hormone (FSH), Serum
	HGH	Growth Hormone, Serum
	LH	Luteinizing Hormone (LH), Serum
	MCRPL	Macroprolactin, Serum
	NSE	Neuron-Specific Enolase (NSE), Serum
	PLPMA	Prolactin, Pituitary Macroadenoma, Serum
	PRL	Prolactin, Serum
Bio	ogenic An	nines
	CATU	Catecholamine Fractionation, Free, 24 Hour, Urine
	CATP	Catecholamine Fractionation, Free, Plasma
	HVA	Homovanillic Acid, 24 Hour, Urine
	HVAR	Homovanillic Acid, Random, Urine
	HIAA	5-Hydroxyindoleacetic Acid, 24 Hour, Urine
	METAF	Metanephrines, Fractionated, 24 Hour, Urine
	PMET	Metanephrines, Fractionated, Free, Plasma
	METAR	Metanephrines, Fractionated, Random, Urine
	SERU	Serotonin, 24 Hour, Urine
	SERWB	Serotonin, Blood
	VH	Vanillylmandelic Acid and Homovanillic Acid, Random, Urine
	VMA	Vanillylmandelic Acid, 24 Hour, Urine
	VMAR	Vanillylmandelic Acid, Random, Urine
Ga	strointes	stinal
	L3AFP	Alpha-Fetoprotein (AFP) L3% and Total, Hepatocellular Carcinoma Tumor Marker, Serum
	AFPPT	Alpha-Fetoprotein (AFP), Peritoneal Fluid
	AFP	Alpha-Fetoprotein (AFP) Tumor Marker, Serum

☐ AMLPC Amylase, Pancreatic Cyst Fluid

gen 19-9 (CA 19-9), uid gen 19-9 (CA 19-9),
gen 19-9 (CA 19-9),
gen 19-9 (CA 19-9),
Antigen (CEA), uid
Antigen (CEA),
Antigen (CEA), Serum
Serum
oxy Prothrombin, Serum
d, Colorectal Cancer e, Immunochemical,
rcinoma Risk Panel e, Serum
cetic Acid, 24 Hour, Urine
nolase (NSE), Serum
ptide, Plasma
r, Urine
nal Polypeptide, Plasma
(AFP), Spinal Fluid
(AFP) Tumor Marker,
ionic Gonadotropin, m
ionic Gonadotropin, al Fluid
Antigen (CEA),
Antigen (PSA) I
Antigen (PSA) Screen,
dex (phi), Serum
Antigen (PSA), rum

Gynecolog	у
□ BHCG	Beta-Human Chorionic Gonadotropin, Quantitative, Serum
□ CA25	Cancer Antigen 125 (CA 125), Serum
☐ HE4	Human Epididymis Protein 4, Serum
□ INHA	Inhibin A, Tumor Marker, Serum
□ INHAB	Inhibin A and B, Tumor Marker, Serum
□ INHB	Inhibin B, Serum
□ ROMA	ROMA Score (Ovarian Malignancy Risk Algorithm), Serum
Pulmonary	1
□ PF199	Carbohydrate Antigen 19-9 (CA 19-9), Pleural Fluid
□ DECE A	
□ PFCEA	Carcinoembryonic Antigen (CEA), Pleural Fluid
□ PFCEA	
□ NSE	Pleural Fluid Neuron-Specific Enolase (NSE), Serum
□ NSE  ADDITION	Pleural Fluid Neuron-Specific Enolase (NSE), Serum
□ NSE  ADDITION	Pleural Fluid  Neuron-Specific Enolase (NSE), Serum  AL TESTS
□ NSE  ADDITION	Pleural Fluid  Neuron-Specific Enolase (NSE), Serum  AL TESTS
□ NSE  ADDITION	Pleural Fluid  Neuron-Specific Enolase (NSE), Serum  AL TESTS
□ NSE  ADDITION	Pleural Fluid  Neuron-Specific Enolase (NSE), Serum  AL TESTS
□ NSE  ADDITION	Pleural Fluid  Neuron-Specific Enolase (NSE), Serum  AL TESTS
□ NSE  ADDITION	Pleural Fluid  Neuron-Specific Enolase (NSE), Serum  AL TESTS
□ NSE  ADDITION	Pleural Fluid  Neuron-Specific Enolase (NSE), Serum  AL TESTS
□ NSE  ADDITION	Pleural Fluid  Neuron-Specific Enolase (NSE), Serum  AL TESTS
□ NSE  ADDITION	Pleural Fluid  Neuron-Specific Enolase (NSE), Serum  AL TESTS
□ NSE  ADDITION	Pleural Fluid  Neuron-Specific Enolase (NSE), Serum  AL TESTS
□ NSE  ADDITION	Pleural Fluid  Neuron-Specific Enolase (NSE), Serum  AL TESTS
□ NSE  ADDITION	Pleural Fluid  Neuron-Specific Enolase (NSE), Serum  AL TESTS
□ NSE  ADDITION	Pleural Fluid  Neuron-Specific Enolase (NSE), Serum  AL TESTS